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Background: Plasmodium vivax causes almost half of all malaria cases in Asia and is recognised as a significant
cause of morbidity. In recent years it has been associated with severe and fatal disease. The extent to which P. vivax
contributes to death is not known.
Methods: To define the epidemiology of mortality attributable to vivax malaria in southern Papua, Indonesia, a
retrospective clinical records-based audit was conducted of all deaths in patients with vivax malaria at a tertiary
referral hospital.
Results: Between January 2004 and September 2009, hospital surveillance identified 3,495 inpatients with P. vivax
monoinfection and 65 (1.9%) patients who subsequently died. Charts for 54 of these 65 patients could be reviewed,
40 (74%) of whom had pure P. vivax infections on cross-checking. Using pre-defined conservative criteria, vivax malaria
was the primary cause of death in 6 cases, a major contributor in 17 cases and a minor contributor in a further 13
cases. Extreme anaemia was the most common primary cause of death. Malnutrition, sepsis with respiratory and
gastrointestinal manifestations, and chronic diseases were the commonest attributed causes of death for patients
in the latter two categories. There were an estimated 293,763 cases of pure P. vivax infection in the community
during the study period giving an overall minimum case fatality of 0.12 per 1,000 infections. The corresponding
case fatality in hospitalised patients was 10.3 per 1,000 infections.
Conclusions: Although uncommonly directly fatal, vivax malaria is an important indirect cause of death in
southern Papua in patients with malnutrition, sepsis syndrome and chronic diseases, including HIV infection.
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Almost three billion people are estimated to be at risk of
Plasmodium vivax malaria, the vast majority of whom
live in south and southeast Asian countries [1,2]. In
endemic regions, this relapsing disease is responsible for
substantial morbidity, mostly associated with recurrent
bouts of fever, anaemia [3] and adverse pregnancy out-
comes [4,5]. Plasmodium vivax is not generally regarded
as sufficiently virulent to cause death. Notwithstanding
this benign reputation, over the last two to three* Correspondence: rprice@menzies.edu.au
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unless otherwise stated.decades, there have been multiple case studies of fatal
vivax malaria [6,7]. More recently, hospital and outpatient
surveillance systems have shown that P. vivax-associated
mortality may be occurring with greater frequency than
previously thought or reported [8-11].
In Papua, Indonesia, P. vivax infections exact a consid-
erable toll [8,10]. This reflects the high risk of multiple
recurrences, the presence of high-grade chloroquine-
resistance [12], comparatively high-level endemicity [13]
and a large proportion of relatively non-immune migrants
in the area [14]. The fatality of hospitalised patients
with P. vivax parasitaemia in Timika, southern Papua,
has been estimated to be similar to that of patients with
P. falciparum infections (1.6% versus 2.2% respectively)
[10]. In the present study we aimed to determine thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conducting an audit of the clinical records of all patients
with pure P. vivax infections who died at Mitra Masyarakat
Hospital between January 2004 and September 2009.
Methods
Study site
The geography, climate and demographics of Mimika
District and its capital city, Timika, have been described
elsewhere [4,10]. Our study was based at the Mitra
Masyarakat Hospital (Rumah Sakit Mitra Masyarakat,
RSMM), which, until November 2008, was the only
referral hospital in the south of Papua. This facility
provides treatment to all patients – free of charge for
indigenous Papuan residents and at a nominal cost for
non-Papuans. The hospital has 101 beds, a 24-hour
emergency department, an active outpatient ‘polyclinic’,
and a high care unit with facilities for intravenous infu-
sions but not mechanical ventilation. Radiological services
include X-ray and ultrasonography. Laboratory facilities
are also available for haematologic and biochemical ana-
lysis and basic microscopy, but not for microbiological
culture. In addition to the hospital, there is also a network
of primary health clinics distributed throughout the com-
munity. An established community surveillance network
covers 14 of these clinics and collects data on the total
number of blood smear examinations and the number of
malaria positive films read on a weekly basis.
Malaria transmission in Mimika District is generally
restricted to lowland areas below 1,500 m elevation where
it is associated with efficient mosquito vectors, primarily
the Punctulatus group. The estimated average annual inci-
dence of clinical and asymptomatic malaria is 876
episodes per 1,000 people, 46% due to P. falciparum and
39% due to P. vivax [13]. The point prevalence of asexual
parasitaemia in the community has been estimated at
16.3% (7.7% for P. falciparum and 6.4% for P. vivax) [13].
Prior to March 2006, hospital guidelines recommended
oral quinine plus a 14-day regimen of primaquine for the
treatment of patients with uncomplicated vivax malaria.
After 2006, quinine was switched to dihydroartemisinin-
piperaquine (DHP) for all malaria species. Severe malaria
was treated with intravenous quinine prior to May 2005
and intravenous artesunate thereafter.
Prospective hospital surveillance procedures
The methods of malariometric surveillance at RSMM
hospital have been described elsewhere [10]. Hospital
guidelines dictate that all inpatients should have blood
taken for malaria microscopy at the hospital laboratory.
In a minority of cases, blood smears are also read by local
expert research-based microscopists. Slides are declared
negative after review of a minimum of 100 high-power
microscope fields and if parasitaemia is present thedensity is scored semiquantitatively as 1+ to 4+. In
2004, a random sample of 1,083 positive slides from the
hospital laboratory was re-examined by an independent
expert microscopist with more than 10 years of experience.
The overall concordance between initial and subsequent
readings was 90% (979/1083). In 1.7% (18/1,083) of the
slides, the second reading was negative and in 4% (38/922)
of cases, slides reported as monoinfections were, in fact,
found to be mixed-species infections. In a minority of cases
blood was tested for histidine-rich protein 2 (HRP2) using
the Paracheck Pf® (Orchid Biochemical Systems, Goa, India)
rapid diagnostic test (RDT).
With the aid of an automated alert system, a research
nurse searches the wards for any patient with parasitaemia
at least once per day. A research physician then reviews
patients to determine the presence of severe disease
according to the World Health Organization (WHO) cri-
teria [10,15]. Respiratory distress (oxygen saturation (off
supplemental oxygen) of less than 94% or an age-adjusted
elevation in respiratory rate (>32 breaths per minute in
adults, >40 breaths per minute in children 5- to 14-years
old, >50 breaths per minute in children 2-months to
5-years old, and >60 in babies less than 2-months old),
coma (Glasgow Coma Score <11 or Blantyre Coma
Score <3) and anaemia (haemoglobin <5 g/dL) are rou-
tinely assessed, whereas assessment of the other severity
criteria is less systematic as they generally rely on more
specialised tests or examinations that are only conducted
if clinically indicated.
Death audit
All patients who, according to the prospective surveil-
lance data, had had pure P. vivax infection at any stage
during their final admission and who subsequently died
at RSMM hospital between January 2004 and September
2009 were eligible for inclusion in the death audit. The
data reviewed included 2,937 P. vivax infections and 46
deaths occurring between January 2004 and December
2007 that were included in a previous hospital-based
epidemiological analysis [10]. Those diagnosed by RDT
alone and those who only received a microscopic diag-
nosis of vivax malaria before referral to the hospital were
excluded from the analysis. Data from the clinical notes
were extracted by two physicians experienced in internal
medicine. Information was recorded on a standardised
death audit form and then entered into an EpiData data-
base (version 3.1, EpiData Association, Odense, Denmark).
The audit form documented presenting symptoms, past
medical history, examination findings, laboratory and
radiological investigation results, fulfilment of ‘severity’
criteria, diagnoses given during admission, treatment
received and progress. If Plasmodium species identifica-
tion was available from both hospital and research
cross-check microscopy, the latter was taken as the best
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positive HRP2-based rapid antigen test (Paracheck Pf®,
Orchid Biochemical Systems) was taken as confirmation
of P. falciparum infection even if this was not detected on
standard microscopy. If available, X-rays were interpreted
by a certified infectious diseases specialist who was
blinded to case history. Indicators of severity were only
deemed to be present if the relevant criteria were fulfilled
prior to the preterminal period (defined as within six
hours of death).
After all relevant information had been extracted,
three certified infectious diseases specialists (coauthors
TWY, NMA and RNP) who had not been involved in
the data extraction process independently reviewed the
clinical data available for each case and subsequently
classified the degree to which P. vivax was responsible
for the deaths. This was done according to strict a priori
criteria based on plausible pathological mechanisms
reported in the scientific literature [16] and prior clinical
experience with the disease (Table 1). Any disagreements
in classification of the cause(s) of death were resolved by
consensus. The sole exception to the criteria was for
patients who did not fulfil the rules for inclusion in
Category 1 (vivax malaria as primary cause of death) but
who had no plausible alternative cause of death. In these
instances, vivax malaria was classified as the prime cause
of death. Although well-established to occur as a result
of P. vivax infection alone [16], respiratory distress was
only considered to be due to vivax malaria if there was no
evidence of concomitant bacterial sepsis, conservatively
defined as infiltrates on chest X-ray or any deviation in
white cell count from the age-adjusted normal range [17].
Diarrhoea was conservatively attributed to alternative
causes. Longitudinal cohorts indicate that P. vivax infec-
tion in children results in malnutrition [18], hence severe
malnutrition with two or more documented episodes ofTable 1 A priori criteria for classifying cause of death
Category Category description Clinical criteria
1 Pure vivax malaria the primary
cause of death
Potential mechanisms inclu
not associated with evidenc
2 Pure vivax malaria likely to have
been a major contributor to death
Alternative cause(s) more lik
one of the following mecha
evidence of bacterial sepsis
decreased consciousness or
malaria in the last year
3 Pure vivax malaria likely to have
been a minor contributor to death
Alternative cause(s) more lik
one of the following mecha
the lower limit of normal)
4 Pure vivax malaria unlikely to
have contributed to death
No clear direct pathophysio
contributed to the primary
aSepsis conservatively attributed to bacterial co-infection. Evidence of sepsis define
age-adjusted normal range (birth; 20,000-40,000/mm3, 1 week; 5,000-21,000/mm3, 2
to 5 years; 5,000-12,000/mm3, greater than 5 years; 4,000-10,000/mm3).
bMalnutrition defined as documented malnutrition in the notes or a weight-for-agevivax malaria in the preceding 12 months, was classified
as vivax malaria being a major contributor to death.
Statistical analyses
Data were analysed in STATA® version 10.1 (StataCorp,
College Station, TX, USA) and EpiInfo® version 3.4.3
(Centers for Disease Control and Prevention, Atlanta,
GA, USA). Proportions were compared using the chi-
square test with Yates’ continuity correction or Fisher’s
exact probability test and nonparametric continuous
data, such as patient age, were compared using the
Mann–Whitney U test. For the purposes of incidence
and mortality rate estimation, we assumed a constant
study population of 150,000 people (mid-way between
the Indonesian government census estimates obtained in
2003 and 2007).
Ethical considerations
This study was approved by the ethics committees of the
University of Gadjah Mada, Indonesia (KE.FK.544.EC)
and the Menzies School of Health Research, Australia
(HREC 2010–1397). Since patients underwent no add-
itional interventions above routine medical care, individual
consent was not sought, unless the patient was enrolled in
associated studies.
Results
The epidemiology of vivax malaria in Mimika District
Between January 2004 and September 2009 there were
an estimated 293,763 clinical or subclinical episodes of
vivax malaria in Mimika District [13] resulting in 3,495
admissions to hospital with confirmed P. vivax parasit-
aemia (Figure 1). The number of patients admitted with
malaria showed a bimodal age distribution with peaks
between 0 to 10 and 15 to 35 years (Figure 2). The hos-
pital surveillance system identified 845 (24%) patientsde: coma, extreme anaemia (haemoglobin <3 g/dL), respiratory distress
e of sepsisa, acidosis if associated with severe anaemia or splenic rupture
ely to have led to death but vivax malaria a major contributor through
nisms: haemoglobin <7 g/dL, respiratory distress not associated with
a, acidosis if associated with haemoglobin <7 g/dL, splenic rupture,
malnutritionb with two or more documented episodes of vivax
ely to have led to death but vivax malaria a minor contributor through
nisms: fever, tachycardia or anaemia (haemoglobin between 7 g/dL and
logical mechanism by which vivax malaria could have exacerbated or
cause(s) of death
d as consolidation on chest X-ray or any deviation in white cell count from the
weeks; 5,000-20,000/mm3, 3 months to 12 months; 5,000-15,000/mm3, 1 year
Z-score less than -3, according to the WHO Child Growth Standards [19].
Figure 1 Distribution of malaria cases, hospital admissions and deaths in Mimika District between January 2004 and September 2009
(to scale). The figures for the community case work load (overall and febrile) were generated from the hospital surveillance as well as a previous
prevalence and treatment seeking survey [13]. Abbreviations: Pf; Plasmodium falciparum, Pv; Plasmodium vivax, Po; Plasmodium ovale, Pm; Plasmodium
malariae, Mix; mixed Plasmodium species infection.
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manifestations of malaria: anaemia in 19% (n = 652),
respiratory distress in 5.3% (185) and coma in 1.6% (55).
The corresponding figures for the 10,821 patients with
P. falciparum infection were 23% (2,526) with severe
manifestations: severe anaemia in 13% (1,451; P <0.001
for difference compared to P. vivax), respiratory distress
in 5.0% (539, P = 0.5) and coma in 2.8% (298, P <0.001).
During the same period there were 311 deaths in hos-
pitalised patients with malaria, 65 (21%) of whom were
reported to have had pure P. vivax parasitaemia. Based
on these data, there were no differences in the age distri-
bution (P = 0.74) or the proportion of females (P = 0.48)
or non-Papuans (P = 0.90) in those who died with P. vivax
parasitaemia versus those who survived.
The death audit
In total, 54 (83%) of the 65 relevant clinical charts were
available for the death audit (Figure 3). The 11 patients
for whom charts were not available had similar baseline
characteristics to the remaining 54 patients. Two patientswere excluded from the audit because they received
their parasitological diagnoses outside of the hospital
or their diagnoses were based exclusively on results
from a RDT.
Blood films were available for cross-checking in 19%
(10/52) of the remaining cases (Table 2) and altered the
hospital diagnosis from P. vivax monoinfection to mixed
P. vivax/P. falciparum infection in one case. Paracheck
Pf® (Orchid Biochemical Systems) tests were performed
in 19% (10/52) of cases and altered the diagnosis for one
further case from P. vivax to mixed infection. On review
of the notes and the above laboratory findings, a total of
12 of 52 cases (23%) had been incorrectly coded as
infection with pure P. vivax infections. Six of these cases
had been reclassified as mixed infections and six were
due to coding errors. The remaining 40 (77%) patients
had pure P. vivax parasitaemia according to the best
available evidence. Chest X-rays were available for review
in 26 of these cases.
Four patients died of causes thought unlikely to be
related to P. vivax infection (Figure 3); two due to road
Figure 2 Age distribution of patients admitted to Mitra Masyarakat Hospital with malaria between January 2004 and September 2009
by Plasmodium species.
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to tuberculous meningoencephalitis. These patients were
excluded from further analysis. The remaining patients
were classified as Category 1 (P. vivax infection the prime
cause of death) in 6 cases, Category 2 (P. vivax infection a
major contributor) in 17 cases and Category 3 (P. vivax
infection a minor contributor) in 13 cases. Of these 36
patients, 23 (64%) had presented to the hospital in the
12 months preceding their death. The median number
of preceding presentations was 5 (range 1 to 17) and
the proportion of these presentations due to malaria was
25% (41/161). Malnutrition was recorded in 16 (44%)
patients and was present in 64% (14/22) of children less
than five-years old who died compared to 14% (2/14) of
those five-years old and older. Patients who had pre-
sented to the hospital with malaria over the preceding
12 months were at greater risk of malnutrition (59%,
10/17) compared to those with no documentation of
prior presentation with malaria (31%, 6/19), although
this did not reach statistical significance (P = 0.18).
The median age of the patients in Category 1 was
1.7 years (interquartile (IQ) range 0.71 to 21 years),
3.0 years (IQ range 1.5 to 26 years) in Category 2
and 4 years (IQ range 2.0 to 43 years) in Category 3,P = 0.23. There was a predominance of females in all
three categories (83% (5/6), 77% (13/17) and 54% (7/13),
respectively), although this was also the case in hos-
pitalised patients with vivax malaria as a whole (60%
(2,081/3,495)).
Overall, the most prominent manifestation of severity
was respiratory distress which was present in 74% (26)
of the 35 patients in whom this could be assessed. In
total, 83% (19/23) of children (≤15 years) had respiratory
distress compared with 58% (7/12) of adults; P = 0.36.
Respiratory distress was present in all of the ten patients
with severe anaemia compared to only 62% (15/24) of
those patients without severe anaemia; P = 0.07.
Four (13%) of the 31 patients in whom a Glasgow or
Blantyre Coma Score was reported fulfilled criteria for
cerebral malaria prior to the preterminal period (Table 2
patients #14, #22, #27 and #32). In one case a lumbar
puncture was suggestive of bacterial meningitis. The other
three deaths were not deemed to be primarily attributable
to vivax malaria.
Haematology testing was available in 97% (35/36) of
patients in the death audit. There was a non-statistically
significant association between anaemia and acidosis
(rs = 0.45, P = 0.09; Figure 4). Severe anaemia was present
Figure 3 Death audit profile.
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had blood gas analyses (three of the acidotic patients also
had severe anaemia and eight had respiratory distress).
Severe thrombocytopaenia was relatively common with
19% (7/35) of patients having a platelet concentration
of less than 50 × 109 per litre and 14% (5/35) less than
20 × 109 per litre. Three of the 13 patients tested (23%)
fulfilled the WHO criterion for hyperbilirubinaemia
(>42.75 mmol/L), two of whom succumbed to vivax
malaria as a direct cause of death. Two of the 28 patients
assessed (7%) had hypoglycaemia (glucose <2.2 mmol/L).
Six of nineteen patients assessed (32%) had a creatinine
concentration above 230 μmol/L (the WHO criterion for
severe malaria).
Three recurring patterns, and potential mechanisms,
of death emerged. The first mechanism was extreme
anaemia (haemoglobin <3 g/dL) which was deemed to
be the cause of death in five of the six (83%) patients in
Category 1. The second was a combination of severe
malnutrition and vivax malaria, often with additional
sepsis with respiratory or gastrointestinal manifesta-
tions. Overall, 16 (44%) of the 36 vivax-associated
deaths were in patients with documented malnutrition,
including three patients who had a WHO weight-for-
age Z-score of less than −3 [19]. The third patternconstituted vivax malaria in association with chronic
or subacute morbidity, such as chronic kidney disease
(n =3), HIV infection (n =5) or active tuberculosis
(n =2).Overall risks
After correcting for errors in parasite species identifica-
tion, P. vivax was found to have caused or contributed
to a minimum of 36 deaths over the 69-month accrual
period, corresponding to a minimum case fatality of 10.3
per 1,000 (36/3,495) hospitalised patients with P. vivax
infection (Table 3). From the concurrent community
surveillance and a household survey of treatment seeking
behaviour [13] an estimated 293,763 cases of vivax parasit-
aemia occurred in Mimika District over the study accrual
period, giving rise to an overall estimated minimum case
fatality rate of 0.12 per 1,000 infections. The upper limits
for the hospital and community fatality estimates were
16.9 and 0.63 per 1,000, respectively (see the footnote of
Table 3 for the assumptions underlying this sensitivity
analysis). The case fatality of vivax malaria in children
under five years of age compared with those five years of
age or older was 14.9 versus 7.0 per 1,000 in the hospital
and 0.26 versus 0.07 per 1,000 in the community.
Table 2 Clinical details of the patients whose deaths were associated with vivax malaria




















1 19y 1d 40 N 2 ++++ 2.2 7,000 11 135.6
2a 1y7m 1d 7 Y 1 ++ 4.7 8,000 142 -
3 24y 4d 56 N 0 ++++ 2.6 16100 51 29.2
4b 10 m 3d 7 Y 0 ++++ 1.9 11,800 64 -
5 1y9m 2d 11 N 0 ++++ 1.7 20,100 139 116.3
2. Major
contributor
6 3m26d 5 h - N 0 + 2.8 29,000 123 -
7a 4y4m 2d 10 Y 0 ++++ 8.6 14,300 13 13.5
8a 3y1m 3 h 12 N 0 ++ - - - -
9 1y9m 7d 8 Y 3 +++ 9.2 11,000 163 -
10 1y8m 4d 8 Y 0 ++++ 5.1 4,200 154 -
11 1y8m 1d - Y 0 +++ 7.3 13,900 13 -
12a 1y3m 9d 6 Y 3 +++ 12.5 25,300 136 5.3
13 1y 7d 6 Y 0 ++ 7.9 8,300 105 -
14 38y 13d 26 Y 0 +++ 6.3 14,300 55 -
15 2y 2d 12 Y 0 + 4.4 10,600 21 23.4
16 1y5m 17d 5 Y 3 ++ 6.7 9,500 262 -
17 27y 5d - N 1 + 6.5 3,800 80 -
18 1y23d 6 h 9 N 0 +++ 5.8 4,700 229 -
19 34y 8 h 50 N 0 ++ 5.8 14,100 252 -
20b 61y 6d 50 N 0 + 4.1 3,500 9 21.7
21a,
b
25y 5 h 75 N 0 + 6.2 23,700 22 -
22b 3y 1d 11 N 0 ++ 9.4 9,600 152 -
23b 14y 8d - N 0 +++ 2.1 4,200 89 19.0
3. Minor
contributor
24 2y4m 6d 9 Y 1 ++ 13.0 12,600 231 40.4
25 59y 3d 50 N 0 + 10.5 35,500 173 33.5
26 2y10m 5d 12 Y 1 + 9.0 13200 124 -
27a 18y 1d 50 N 0 ++ 15.5 16,100 100 -
28a 60y 1d 37 N 0 + 11.5 11,800 119 -
29 1y8m 1d 7 N 1 ++ 9.8 79,300 580 -
30 24y 5d 33 N 2 + 4.7 1,500 85 6.7
31 5m4d 12d 7 N 0 ++ 13.0 7,200 107 -
32 1y8m 1d 6 Y 0 ++++ 10.2 19,700 110 -
33 55y 4d 60 N 0 ++++ 10.1 19,500 55 -
34 4y 1d 16 N 0 + 11.2 22,700 461 -
35 31y 10d 38 Y 1 + 9.9 3,700 114 3.4
36 3y6m 15d 12 Y 2 ++ 8.9 27,700 3 63.3
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2a - - - - 1,1,1 Vivax malaria Malnutrition
3 248 6.1 - Resolving minor RLL
consolidation compared
with film 1 month prior
1,1,1 Vivax malaria with
extreme anaemia
and renal failure
4b - 13.5 3.0 Day 0 – normal Day
2 – whiteout of R lung
and part of L lung.
Pulmonary oedema in
remainder of L lung
























8a - - - Normal 2,2,2 Respiratory
tract infection
Vivax malaria
9 - - - - 1,2,2 Malnutrition
with sepsis
Vivax malaria










12a - 6.8 - 2,2,3 Diarrhoeal disease Malnutrition
Vivax malaria





14 106 6.0 - Minor chronic changes
in LLL
2,2,2 AIDS Vivax malaria
Malnutrition




16 - 6.0 - Diffuse changes
consistent with
pneumonia, R > L
2,2,2 AIDS Vivax malaria
Malnutrition
Tuberculosis
17 - - 19.2 - 2,2,2 AIDS Vivax malaria
18 44 8.7 9.3 RUL consolidation 2,2,2 Bronchopneumonia
associated with acidosis
Vivax malaria
19 - 4.9 2.2 Bilaterally increased lung
markings, R > L,



















97 15.4 - - 2,2,2 GI bleeding
secondary to NSAID
Vivax malaria
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Table 2 Clinical details of the patients whose deaths were associated with vivax malaria (Continued)




in the day – collapsed L
lung with ETT in R main
















24 - 6.9 - - 2,3,3 Diarrhoeal disease Sepsis
Malnutrition
Vivax malaria
25 228 4.2 - - 3,3,3 Respiratory sepsis COPD Vivax
malaria Ischemic
heart disease
26 12 5.8 22.8 Dense, bilateral patchy









28a 600 5.7 - - 3,3,4 Hepatorenal syndrome Vivax malaria
Possible bacterial
infection
29 - 2.4 9.9 CXR 2 days prior showed
infiltrate obscuring L
heart border
3,3,3 Respiratory tract infection with
overwhelming sepsis and acidosis
Vivax malaria
Malnutrition
30 132 5.7 21.9 Worsening RML
consolidation and
cavitation compared
with previous films. L




3,3,3 AIDS with tuberculosis Vivax malaria
31 - - 13.9 Infiltrate at R hilum 3,4,3 Bronchopneumonia associated with
acidosis
Vivax malaria




33 521 3.7 - Increased lung
markings bilaterally
3,3,3 Sepsis and renal failure Vivax malaria
34 - 6.0 - - 3,3,3 GI sepsis Vivax malaria
35 131 4.6 - - 3,3,3 HIV associated enteropathy Malnutrition
Vivax malaria
36 - - 33.2 Poor inspiratory effort,
unable to assess





aResearch microscopy done; bParacheck Pf® done. AIDS; acquired immunodeficiency syndrome, ARDS; acute respiratory distress syndrome, CXR; chest X-ray,
d; day, h; hour, ETT; endotracheal tube, GI; gastrointestinal, HIV; human immunodeficiency virus, L; left, LLL; left lower lobe, m; month, NSAID; non-steroidal
anti-inflammatory drug, Pv; Plasmodium vivax, R; right, RLL; right lower lobe, RML; right middle lobe, RUL; right upper lobe, y; year. To comply with the BMC
policy on patient confidentiality, details on gender were removed from the table to ensure there were less than three indirect identifiers per patient.
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Over recent years, malariometric surveillance in southern
Papua has identified a significant number of individuals
who have died following P. vivax infection. Our previous
publication based on an earlier set of surveillance data
reported an overall risk of death in patients admitted with
vivax malaria of 1.6%, raising significant concerns that the
virulence of this organism had been underestimated [10].In the current analysis we used a priori definitions to
classify the contribution of vivax malaria to those deaths.
We excluded individuals with mixed Plasmodium species
infections and used conservative criteria to define poten-
tial concomitant bacterial sepsis. Our results highlight that
over a six year period, a minimum of 36 deaths could be
at least partially attributed to P. vivax infection and that in
six cases vivax malaria was most likely the primary cause
Figure 4 Relationship between anaemia and acidosis in vivax-associated deaths. Diamond = Category 1, Squares = Category 2 and
Triangles = Category 3. rs = 0.45, P = 0.09.
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admitted to hospital and 1 in 8,160 for the community as
a whole. Children younger than five years old were at a
two- to four-fold greater risk of death compared to those
older than five years.
Five of the patients in the study died of extreme
anaemia (probably as a result of high-output cardiac
failure and acidosis), while severe anaemia was a major
contributor in five other fatal cases. A study from
Venezuela suggests that in areas of mixed species en-
demicity, anaemia may be a more frequent and severe
sequel of vivax compared with falciparum malaria [20].
In Timika, the mean reduction in haemoglobin and risk
of severe anaemia is greater for infants (<1 year of age)
infected with P. vivax when compared with P. falciparum
and, thereafter, the haematologic impact of P. falciparum
exceeds that of P. vivax, [3,21]. We have shown previously
that 12% of all deaths at the RSMM are attributable to
patients with severe anaemia and overall 6% of all cases of
severe anaemia are attributed to vivax malaria [3].
Overall, nearly half (44%) of the vivax-associated deaths
had evidence of malnutrition and a high proportion of
these individuals also had clinical or radiological evidence
of possible concomitant bacterial infection. Chronic P.
vivax infections have been implicated in a protein-wasting
condition akin to kwashiorkor, in both induced [22] and
natural infection [23]. Indeed, the evidence that P. vivax
causes malnutrition is stronger than that for P. falciparum
[24]. It is also likely that there is an epidemiological, and
possibly a biological, association between malnutrition
and a greater risk of P. vivax severe disease [25], as has
been noted previously in patients infected with P.falciparum [26]. While this relationship is likely bidir-
ectional, our study supports previous literature suggest-
ing that malnutrition significantly worsens the outcome
of infectious disease and implicates vivax malaria as not
only a potential cause of malnutrition, but also a subse-
quent precipitating cause of death in those with signifi-
cant malnutrition [16].
More than 70% of audited individuals fulfilled the criteria
for respiratory distress. Previous work has suggested that
vivax-associated lung dysfunction may occur from an in-
flammatory response in the pulmonary microvasculature,
exacerbated by treatment [27], causing increased capillary
permeability, alveolar endothelial damage and chest X-ray
infiltrates [28-30]. One infant had an acute respiratory
distress-type picture. Bilateral lung infiltrates consistent
with acute lung injury were seen in 15% of all adult vivax-
associated deaths and in a third of those who had chest
X-rays. Severe anaemia and metabolic acidosis are also
likely to be key determinants, particularly in children,
in whom lung injury is less common than in adults.
Eight of the nine patients with acidosis were found to
be in respiratory distress as were all ten patients with
severe anaemia.
Studies of P. falciparum infection in African children
have shown high coprevalence of pneumonia, meningitis
and bacteraemia in children with severe malaria [31-33],
the largest of which demonstrated a strong association
between coinfection and an increased risk of death [33].
A study in Papua New Guinea has also highlighted the
importance of respiratory distress in vivax malaria, although
the degree to which this was attributable to P. vivax infec-
tion, associated anaemia or comorbid pneumonia was
Table 3 Case fatality per 1,000 patients with vivax malaria









<5 years 14.9 19.6 0.26 1.13
(95% CI 9.3 to 22.4) (95% CI 13.1 to 28.0) (95% CI 0.16 to 0.40) (95% CI 0.87 to 1.33)
(22/1,480c) (29/1,480) (22/84,028) (90.6/84,028)
≥5 years 7.0 15.1 0.07 0.45
(95% CI 3.9 to 11.8) (95% CI 10.2 to 21.5) (95% CI 0.04 to 0.11) (95% CI 0.36 to 0.55)
(14/1,986c) (30/1,986) (14/209,735) (93.8/209,735)
All 10.3 16.9 0.12 0.63
(95% CI 7.2 to 14.20 (95% CI 12.9 to 21.7) (95% CI 0.09 to 0.17) (95% CI 0.54 to 0.72)
(36/3,495) (59/3,495) (36/293,763) (184.4/293,763)
aUpper limits were calculated assuming the following: 1) all of the patients for whom notes were not available died of causes related to P. vivax infection; 2) an
equal number of deaths were miscoded as being attributable to P. falciparum as were miscoded as being attributable to P. vivax; bdenominators include hospital
and community patients with P. vivax, estimated from the total number of cases seen in our community surveillance network multiplied by the reciprocal of the
proportion who sought treatment at our network facilities (40%, established from a house-to-house survey of treatment seeking behaviour [3]). To calculate the
upper limits, the same assumptions were made as in the hospitalised patients except we also multiplied the number of deaths by the reciprocal of 32% (the
proportion of deaths estimated to occur outside of hospital (unpublished data)); ca small proportion of individuals in the active surveillance had an unknown age.
N; number, D; denominator.
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in our study, we conservatively regarded any deviation in
white cell count or infiltrates on chest X-ray as evidence
of concomitant bacterial infection. In other studies, albeit
without routine blood cultures for bacteraemia, severe
and fatal sepsis syndromes have been attributed to vivax
malaria [35]. Given the potential for P. vivax to cause an
intense inflammatory response [36] and/or lung injury/
infiltrates [27] it is likely that we have significantly overes-
timated the contribution of infectious comorbidities and
underestimated the direct contribution of vivax malaria
alone to sepsis, lung injury and death. Nevertheless, our
results suggest that, as with falciparum malaria, there may
be a potentially fatal interaction between vivax malaria
and bacterial infection, particularly pneumonia. To clarify
this interaction, prospective studies of severe vivax malaria
syndromes need to include systematic investigation for
concomitant bacterial infection, including blood cultures
[37]. Until then, our findings suggest the need for
aggressive antimalarial treatment in patients with evidence
of coinfection, and also indicate that mono-infected
patients with vivax malaria who show signs of severe
disease should be investigated and treated for associ-
ated bacterial sepsis.
HIV infection is now recognised as a major con-
tributor to the development of severe and fatal disease
in P. falciparum malaria [38]. Fourteen percent of vivax-
associated deaths were in patients with documented HIV
co-infection, which, with the recent rapid increase in HIV
infection in Papua [39] and the retrospective study design,
is likely to be an underestimate of its contribution. While
P. vivax may act as the final precipitating cause of death
in HIV infected individuals, a potential role for HIV inexacerbating the severity of vivax malaria, as occurs
with P. falciparum, requires further investigation.
Our study has several important limitations. According
to laboratory reports, 12 of the 54 patients in the death
audit were actually shown to be suffering from P. fal-
ciparum or mixed species infections. Since we did not
systematically review all P. falciparum deaths, it is possible
that similar miscoding occurred in the opposite direction
(for example low density P. vivax parasitaemia missed on
blood smear examination). This would have resulted in an
underestimation of the true incidence of deaths due to P.
vivax infection. Our sensitivity analysis reported in Table 3
assumes that an equal number of deaths were miscoded
as being attributable to P. falciparum as were miscoded as
being attributable to P. vivax.
Differentiating P. vivax from P. falciparum early ring
(trophozoite) stages using standard microscopy is fraught
with error. Despite high concordance (90%) of hospital
microscopy results and an independent expert’s findings,
it is likely that a degree of misdiagnosis occurred, even in
cases where cross-check microscopy was performed. Fully
quantifiable parasitaemias were not available to the adjudi-
cating physicians; however, the semi-quantitative scoring
gave an indication of relative parasite density.
Rapid diagnostic tests were only done in a minority of
cases. Most HRP2-based tests have been shown to be
highly sensitive for the detection of falciparum malaria;
therefore, a significant biomass of P. falciparum would
have been unlikely in patients who tested negative [40].
For the remaining patients, it is possible that microscopy
may have missed subpatent P. falciparum parasitaemias.
Siripoon et al. found that 13% of patients who had been
diagnosed with P. vivax monoinfections in Thailand also
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testing [41]. Because PCR diagnostics are still not widely
available in endemic areas, this is unlikely to have a bearing
on the clinical classification of malaria or its treatment. It
does, however, limit our ability to categorically incriminate
P. vivax monoinfection as a cause of fatal disease.
Previous treatment seeking studies in southern Papua
estimate that almost 68% of deaths occur outside of
hospital (unpublished data). We incorporated this crude
proportion in the sensitivity analysis but were unable to
make more subtle adjustments based on differences in the
demographic and causative distribution of those deaths.
Conclusion
We have shown that in southern Papua, mortality primarily
attributable to P. vivax infection may occur but that indir-
ect contribution to death in those with comorbidities, such
as malnutrition, HIV and possible bacterial sepsis, is a more
common scenario. Future research should include post-
mortem studies and detailed clinical and microbiological
investigations of severe cases of vivax malaria to character-
ise pathogenic mechanisms and elucidate better therapeutic
strategies by which fatal outcomes may be averted [42]. If
the overall burden of P. vivax is to be appreciably de-
creased, practical, short-course, sterilising drug regimens
must be developed that reliably prevent relapses and reduce
transmission of this complicated disease.
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